Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.75 |
| ▸ | LCK | P06239 | 6/20 | 0.65 |
| ▸ | FYN | P06241 | 6/20 | 0.65 |
| ▸ | YES1 | P07947 | 6/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.65 |
| ▸ | KDR | P35968 | 6/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408973 | 1.00 | SRC (0.75) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6389502 | 0.91 | SRC (0.64) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6389508 | 0.91 | SRC (0.64) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6394684 | 0.90 | SRC (0.80) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6394677 | 0.90 | SRC (0.80) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6389520 | 0.86 | SRC (0.67) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6389522 | 0.86 | SRC (0.67) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6393649 | 0.86 | SRC (0.68) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6393654 | 0.86 | SRC (0.68) | SRCLCKFYNYES1FGFR1 | |
| SCHEMBL6405174 | 0.85 | SRC (0.63) | SRCLCKFYNYES1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | SRC 260/4885LCK 357/4885FYN 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.